The vabysmo market research report is one of a series of new reports that provides vabysmo market statistics, including vabysmo industry global market size, regional shares, competitors with a vabysmo market share, detailed vabysmo market segments, market trends and opportunities, and any further data you may need to thrive in the vabysmo industry. This vabysmo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The growth in the forecast period can be attributed to growing prevalence of retinal diseases, rising awareness about eye diseases, rising cases of AMD, rising incidence of ophthalmic conditions, and rising prevalence of diabetes. Major trends in the forecast period include technological advancements, dual mechanism therapies, imaging technologies, telemedicine, and artificial intelligence.
The increasing prevalence of ophthalmic conditions is anticipated to drive the growth of the vabysmo market. Ophthalmic conditions encompass a wide range of eye health issues, from common problems such as dry eyes to more severe diseases such as cataracts, glaucoma, and macular degeneration. The rise in these conditions is linked to several factors, including an aging population, higher rates of diabetes, lifestyle choices, advancements in detection technologies, and longer life expectancies. Vabysmo aids in treating these conditions by targeting and inhibiting key proteins that cause abnormal blood vessel growth and fluid leakage in the eye. This helps improve vision and reduces the risk of further damage in diseases such as age-related macular degeneration (AMD) and diabetic macular edema (DME), making it an essential treatment for protecting vision. For example, in September 2023, the Association of Optometrists reported that in 2022, England had 22,552 new vision impairment certifications, with 1,344 related to diabetic eye disease, 3,614 to glaucoma, and 10,865 to AMD. As the incidence of ophthalmic conditions continues to rise, the demand for vabysmo is expected to grow.
The expanding aging population is also expected to drive the vabysmo market. As life expectancy increases and birth rates decline, the proportion of elderly individuals is growing, contributing to a larger aging population. This demographic shift is mainly due to improvements in healthcare and a decrease in birth rates. Vabysmo is particularly beneficial for the elderly, as it helps treat retinal diseases that can lead to vision loss, a common concern among older adults. For instance, the Population Reference Bureau reported in January 2024 that the number of Americans aged 65 and older is expected to rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. As the aging population grows, so will the demand for treatments such as vabysmo.
A significant trend in the vabysmo market is the emphasis on obtaining regulatory approvals to broaden its use and make it accessible to a wider patient population. Regulatory approval ensures that a product meets safety, efficacy, and quality standards, which helps build consumer trust and provides legal protection. In December 2024, Roche Holding AG received approval from the European Medicines Agency for its Vabysmo prefilled syringe, which is used to treat three retinal conditions: neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema caused by retinal vein occlusion (RVO). These conditions affect over nine million people in Europe. The Vabysmo prefilled syringe, the first of its kind featuring a bispecific antibody, offers a convenient and ready-to-use option, paired with a CE-marked needle for intravitreal injections. Targeting both Angiopoietin-2 (Ang-2) and VEGF-A pathways, the treatment stabilizes blood vessels, reduces inflammation, and improves vision. This innovation not only streamlines the administration process for retina specialists but also reduces the treatment burden for patients.
The key company operating in the vabysmo market is F. Hoffmann-La Roche AG.
North America was the largest region in the vabysmo market in 2024. The regions covered in vabysmo report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the vabysmo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Vabysmo is a prescription medication used to treat retinal diseases, including age-related macular degeneration (AMD) and diabetic macular edema (DME). It works by inhibiting both VEGF and Ang-2, which helps reduce retinal fluid buildup and prevent vision loss. Vabysmo is administered via injection into the eye, offering a long-acting treatment with fewer injections compared to traditional therapies.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for vabysmo include wet age-related macular degeneration (wAMD), diabetic macular edema (DME), diabetic retinopathy (DR), uveitis, and retinal vein occlusion. Wet AMD is characterized by the growth of abnormal blood vessels under the retina, leading to vision loss, particularly in older adults. Vabysmo is available in injectable solutions and pre-filled syringes. It is distributed through various channels such as hospital pharmacies, retail pharmacies, specialty pharmacies, and online pharmacies. The medication is used by various end-users, including adults and geriatric patients.
The vabysmo market consists of sales of prefilled syringes, preservative-free formulation, vials for reconstitution, and injection. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to growing prevalence of retinal diseases, rising awareness about eye diseases, rising cases of AMD, rising incidence of ophthalmic conditions, and rising prevalence of diabetes. Major trends in the forecast period include technological advancements, dual mechanism therapies, imaging technologies, telemedicine, and artificial intelligence.
The increasing prevalence of ophthalmic conditions is anticipated to drive the growth of the vabysmo market. Ophthalmic conditions encompass a wide range of eye health issues, from common problems such as dry eyes to more severe diseases such as cataracts, glaucoma, and macular degeneration. The rise in these conditions is linked to several factors, including an aging population, higher rates of diabetes, lifestyle choices, advancements in detection technologies, and longer life expectancies. Vabysmo aids in treating these conditions by targeting and inhibiting key proteins that cause abnormal blood vessel growth and fluid leakage in the eye. This helps improve vision and reduces the risk of further damage in diseases such as age-related macular degeneration (AMD) and diabetic macular edema (DME), making it an essential treatment for protecting vision. For example, in September 2023, the Association of Optometrists reported that in 2022, England had 22,552 new vision impairment certifications, with 1,344 related to diabetic eye disease, 3,614 to glaucoma, and 10,865 to AMD. As the incidence of ophthalmic conditions continues to rise, the demand for vabysmo is expected to grow.
The expanding aging population is also expected to drive the vabysmo market. As life expectancy increases and birth rates decline, the proportion of elderly individuals is growing, contributing to a larger aging population. This demographic shift is mainly due to improvements in healthcare and a decrease in birth rates. Vabysmo is particularly beneficial for the elderly, as it helps treat retinal diseases that can lead to vision loss, a common concern among older adults. For instance, the Population Reference Bureau reported in January 2024 that the number of Americans aged 65 and older is expected to rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. As the aging population grows, so will the demand for treatments such as vabysmo.
A significant trend in the vabysmo market is the emphasis on obtaining regulatory approvals to broaden its use and make it accessible to a wider patient population. Regulatory approval ensures that a product meets safety, efficacy, and quality standards, which helps build consumer trust and provides legal protection. In December 2024, Roche Holding AG received approval from the European Medicines Agency for its Vabysmo prefilled syringe, which is used to treat three retinal conditions: neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema caused by retinal vein occlusion (RVO). These conditions affect over nine million people in Europe. The Vabysmo prefilled syringe, the first of its kind featuring a bispecific antibody, offers a convenient and ready-to-use option, paired with a CE-marked needle for intravitreal injections. Targeting both Angiopoietin-2 (Ang-2) and VEGF-A pathways, the treatment stabilizes blood vessels, reduces inflammation, and improves vision. This innovation not only streamlines the administration process for retina specialists but also reduces the treatment burden for patients.
The key company operating in the vabysmo market is F. Hoffmann-La Roche AG.
North America was the largest region in the vabysmo market in 2024. The regions covered in vabysmo report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the vabysmo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Vabysmo is a prescription medication used to treat retinal diseases, including age-related macular degeneration (AMD) and diabetic macular edema (DME). It works by inhibiting both VEGF and Ang-2, which helps reduce retinal fluid buildup and prevent vision loss. Vabysmo is administered via injection into the eye, offering a long-acting treatment with fewer injections compared to traditional therapies.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for vabysmo include wet age-related macular degeneration (wAMD), diabetic macular edema (DME), diabetic retinopathy (DR), uveitis, and retinal vein occlusion. Wet AMD is characterized by the growth of abnormal blood vessels under the retina, leading to vision loss, particularly in older adults. Vabysmo is available in injectable solutions and pre-filled syringes. It is distributed through various channels such as hospital pharmacies, retail pharmacies, specialty pharmacies, and online pharmacies. The medication is used by various end-users, including adults and geriatric patients.
The vabysmo market consists of sales of prefilled syringes, preservative-free formulation, vials for reconstitution, and injection. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Vabysmo Market Characteristics4. Vabysmo Market Trends And Strategies5. Vabysmo Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Vabysmo Pricing Analysis & Forecasts30. Global Vabysmo Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Vabysmo Market32. Recent Developments In The Vabysmo Market
3. Vabysmo Market Biologic Drug Characteristics
6. Global Vabysmo Growth Analysis And Strategic Analysis Framework
8. Vabysmo Market Segmentation
9. Global Vabysmo Epidemiology Of Clinical Indications
10. Vabysmo Market Regional And Country Analysis
11. Asia-Pacific Vabysmo Market
12. China Vabysmo Market
13. India Vabysmo Market
14. Japan Vabysmo Market
15. Australia Vabysmo Market
16. South Korea Vabysmo Market
17. Western Europe Vabysmo Market
18. UK Vabysmo Market
19. Germany Vabysmo Market
20. France Vabysmo Market
21. Eastern Europe Vabysmo Market
22. North America Vabysmo Market
23. USA Vabysmo Market
24. Canada Vabysmo Market
25. South America Vabysmo Market
26. Middle East Vabysmo Market
27. Africa Vabysmo Market
28. Vabysmo Market Competitive Landscape And Company Profiles
29. Global Vabysmo Market Pipeline Analysis
33. Vabysmo Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Vabysmo Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on vabysmo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for vabysmo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vabysmo market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Wet Age-Related Macular Degeneration (wAMD); Diabetic Macular Edema (DME); Diabetic Retinopathy (DR); Uveitis; Retinal Vein Occlusion2) By Formulation: Injectable Solutions; Pre-filled Syringes
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Specialty Pharmacies; Online Pharmacies
4) By End User: Adult; Geriatric
Key Companies Profiled: F. Hoffmann-La Roche AG
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- F. Hoffmann-La Roche AG
